EGFR and non-small cell lung carcinoma: Six phase III RCTs (IPASS [20], WJTOG3405 [21], OPTIMAL [22], EUTRAC [23], LUXLUNG3 [24], and LUXLUNG6 [25]), involving 1382 advanced NSCLC chemo-naïve patients, investigated the efficacy of EGFR-TKIs (gefitinib, erlotinib or afatinib) and conventional platinum-based chemotherapy.